Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 17/20 | 0.45 |
| ▸ | THRA | P10827 | 4/20 | 0.43 |
| ▸ | THRB | P10828 | 4/20 | 0.43 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.43 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | ASPH | Q12797 | 1/20 | 0.43 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257456 | 0.96 | EGLN1 (0.48) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL24257784 | 0.86 | PPID (0.43) | EGLN1THRATHRB | |
| SCHEMBL30452335 | 0.86 | PPID (0.43) | EGLN1THRATHRB | |
| SCHEMBL24257810 | 0.82 | RNASEH1 (0.40) | — | |
| SCHEMBL30454412 | 0.82 | RNASEH1 (0.40) | — | |
| SCHEMBL24257827 | 0.81 | RNASEH1 (0.47) | — | |
| SCHEMBL30452343 | 0.81 | RNASEH1 (0.47) | — | |
| Glycine SCHEMBL29248942 | 0.79 | RNASEH1 (0.37) | — | |
| Glycine SCHEMBL30546853 | 0.76 | TDP1 (0.39) | — | |
| Formic Acid SCHEMBL30453300 | 0.76 | EGLN1 (0.62) | EGLN1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4196466-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | EGLN1 19/4885THRA 4382/4885THRB 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.